Literature DB >> 23861282

Catastrophic antiphospholipid syndrome in childhood: presentation with an inferior caval vein mass.

Abdul Alim Abdul Haium1, Mary Sheppard, Michael Rubens, Piers Daubeney.   

Abstract

Venous thromboembolism remains one of the important causes of pulmonary hypertension in children. The causes of venous thromboembolism are varied and include antiphospholipid antibody syndrome (APS). Catastrophic APS (CAPS) is a severe variant of APS characterised by disseminated thrombosis and microangiopathy resulting in multiorgan failure. CAPS can occur independently (primary APS) but mainly occurs in association with systemic lupus erythematosus including the paediatric population. We report a young girl with primary CAPS who presented with pulmonary hypertension and an inferior vena cava mass masquerading as a tumour.

Entities:  

Mesh:

Year:  2013        PMID: 23861282      PMCID: PMC3736204          DOI: 10.1136/bcr-2013-010043

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

Review 1.  Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients.

Authors:  R A Asherson; R Cervera; J C Piette; Y Shoenfeld; G Espinosa; M A Petri; E Lim; T C Lau; A Gurjal; A Jedryka-Góral; H Chwalinska-Sadowska; R J Dibner; J Rojas-Rodríguez; M García-Carrasco; J T Grandone; A L Parke; P Barbosa; C Vasconcelos; M Ramos-Casals; J Font; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  2001-11       Impact factor: 1.889

Review 2.  The catastrophic antiphospholipid syndrome.

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

Review 3.  The catastrophic antiphospholipid (Asherson's) syndrome.

Authors:  Ronald A Asherson
Journal:  Autoimmun Rev       Date:  2006-07-17       Impact factor: 9.754

Review 4.  Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients.

Authors:  R A Asherson; R Cervera; J C Piette; J Font; J T Lie; A Burcoglu; K Lim; F J Muñoz-Rodríguez; R A Levy; F Boué; J Rossert; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  1998-05       Impact factor: 1.889

Review 5.  Catastrophic antiphospholipid syndrome.

Authors:  Joan T Merrill; Ronald A Asherson
Journal:  Nat Clin Pract Rheumatol       Date:  2006-02

Review 6.  The catastrophic antiphospholipid (Asherson's) syndrome and malignancies.

Authors:  W Miesbach; R A Asherson; R Cervera; Y Shoenfeld; J Gomez Puerta; S Bucciarelli; G Espinoza; J Font
Journal:  Autoimmun Rev       Date:  2006-07-21       Impact factor: 9.754

7.  Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients.

Authors:  Silvia Bucciarelli; Gerard Espinosa; Ricard Cervera; Doruk Erkan; José A Gómez-Puerta; Manuel Ramos-Casals; Josep Font; Ronald A Asherson
Journal:  Arthritis Rheum       Date:  2006-08

Review 8.  Malignancies and catastrophic anti-phospholipid syndrome.

Authors:  Wolfgang Miesbach
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 9.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.

Authors:  R A Asherson; R Cervera; P G de Groot; D Erkan; M C Boffa; J C Piette; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

10.  Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".

Authors:  Ricard Cervera; Silvia Bucciarelli; Miguel A Plasín; José A Gómez-Puerta; Joan Plaza; Guillermo Pons-Estel; Yehuda Shoenfeld; Miguel Ingelmo; Gerard Espinos
Journal:  J Autoimmun       Date:  2009-03-26       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.